CDH2 and gastric cancer: Beyond its established role as a canonical marker of EMT [31], aberrant CDH2 expression has been implicated in the aggressive progression of various malignancies, including lung, liver, and gastric cancers, primarily by enhancing cellular migratory and invasive capacities [32,33,34,35].